Search for author "Ralph B. D’Agostino"

• You have accessRestricted access

  Early Myocardial Strain Changes During Potentially Cardiotoxic Chemotherapy May Occur as a Result of Reductions in Left Ventricular End-Diastolic VolumeThe Need to Interpret Left Ventricular Strain With Volumes

  Jennifer H. Jordan, Bunyapon Sukpraphrute, Giselle C. Meléndez, Marie-Pierre Jolly, Ralph B. D’Agostino and W. Gregory Hundley

  Circulation. 2017;135:2575-2577, originally published June 19, 2017

  https://doi.org/10.1161/CIRCULATIONAHA.117.027930

  Download PDF
• You have access

  Early Myocardial Strain Changes During Potentially Cardiotoxic Chemotherapy May Occur as a Result of Reductions in Left Ventricular End-Diastolic Volume

  Jennifer H. Jordan, Bunyapon Sukpraphrute, Giselle C. Meléndez, Marie-Pierre Jolly, Ralph B. D’Agostino, W. Gregory Hundley

  Circulation June 2017, 135 (25) 2575-2577; DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.027930

  

  Figure.

  By Jennifer H. Jordan, Bunyapon Sukpraphrute, Giselle C. Meléndez, Marie-Pierre Jolly, Ralph B. D’Agostino and W. Gregory Hundley

  Midwall circumferential myocardial strain measured with cardiac magnetic resonance in cancer patient...

  Show More

  Midwall circumferential myocardial strain measured with cardiac magnetic resonance in cancer patients before (BL) and 3 months after initiation of chemotherapy categorized by underlying cause of left ventricular ejection fraction (LVEF) decline. Participants with a decline in LVEF resulting from a >10-mL decrease in end-diastolic volume (EDV) exhibited subclinical deteriorations in myocardial strain. Myocardial strain changes were not observed in any other subgroup, including those with end-systolic volume (ESV) changes.

  Show Less
• You have accessRestricted access

  Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Clinical Perspective

  Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh and Laura Mauri On behalf of the DAPT Investigators

  Circulation. 2017;135:1720-1732, originally published February 22, 2017

  https://doi.org/10.1161/CIRCULATIONAHA.116.024835

  Download PDF
• You have access

  Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Clinical Perspective

  Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh, Laura Mauri On behalf of the DAPT Investigators

  Circulation May 2017, 135 (18) 1720-1732; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.024835

  View table

  Table 1.

  By Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh and Laura Mauri

  Baseline and Procedural Characteristics of All Randomly Assigned PatientsShow More

  Baseline and Procedural Characteristics of All Randomly Assigned PatientsShow Less
• You have access

  Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Clinical Perspective

  Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh, Laura Mauri On behalf of the DAPT Investigators

  Circulation May 2017, 135 (18) 1720-1732; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.024835

  View table

  Table 2.

  By Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh and Laura Mauri

  Monthly Rates of Ischemic and Bleeding End Points, by Time Period, in All Randomly Assigned PatientsShow More

  Monthly Rates of Ischemic and Bleeding End Points, by Time Period, in All Randomly Assigned PatientsShow Less
• You have access

  Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Clinical Perspective

  Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh, Laura Mauri On behalf of the DAPT Investigators

  Circulation May 2017, 135 (18) 1720-1732; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.024835

  

  Figure 1.

  By Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh and Laura Mauri

  Monthly cumulative incidence of MI by period (12–15, 15–30, and 30–33 months after PCI) and randomiz...

  Show More

  Monthly cumulative incidence of MI by period (12–15, 15–30, and 30–33 months after PCI) and randomized treatment arm. A, In all randomly assigned patients (n=11 648). B, In patients without PES at index PCI (n=8864). M indicates month; MI, myocardial infarction; PCI, percutaneous coronary intervention, and PES, paclitaxel-eluting stents.

  Show Less
• You have access

  Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Clinical Perspective

  Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh, Laura Mauri On behalf of the DAPT Investigators

  Circulation May 2017, 135 (18) 1720-1732; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.024835

  View table

  Table 3.

  By Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh and Laura Mauri

  Monthly Rates of Ischemic and Bleeding End Points, by Time Period, in Randomly Assigned Patients Not Treated With Paclitaxel-Eluting StentsShow More

  Monthly Rates of Ischemic and Bleeding End Points, by Time Period, in Randomly Assigned Patients Not Treated With Paclitaxel-Eluting StentsShow Less
• You have access

  Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Clinical Perspective

  Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh, Laura Mauri On behalf of the DAPT Investigators

  Circulation May 2017, 135 (18) 1720-1732; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.024835

  

  Figure 2.

  By Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh and Laura Mauri

  Monthly cumulative incidence of MI not related to ST, and MI related to ST, by study period and rand...

  Show More

  Monthly cumulative incidence of MI not related to ST, and MI related to ST, by study period and randomized treatment arm. A, In all randomly assigned patients (n=11 648). B, In patients without PES at index PCI (n=8864). Log-rank P values are for comparison between randomized treatment arms for each MI etiology. MI indicates myocardial infarction; non–ST MI, non-stent thrombosis–related myocardial infarction; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stents; and ST MI, stent thrombosis–related myocardial infarction.

  Show Less
• You have access

  Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Clinical Perspective

  Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh, Laura Mauri On behalf of the DAPT Investigators

  Circulation May 2017, 135 (18) 1720-1732; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.024835

  View table

  Table 4.

  By Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh and Laura Mauri

  Multivariate Predictors of Myocardial Infarction, by Time PeriodShow More

  Multivariate Predictors of Myocardial Infarction, by Time PeriodShow Less
• You have access

  Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Clinical Perspective

  Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh, Laura Mauri On behalf of the DAPT Investigators

  Circulation May 2017, 135 (18) 1720-1732; DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.024835

  

  Figure 3.

  By Ada C. Stefanescu Schmidt, Dean J. Kereiakes, Donald E. Cutlip, Robert W. Yeh, Ralph B. D’Agostino, Joseph M. Massaro, Wen-Hua Hsieh and Laura Mauri

  Difference in monthly incidence of MI between randomized treatment arms, by DAPT score group....

  Show More

  Difference in monthly incidence of MI between randomized treatment arms, by DAPT score group. A, In all randomly assigned patients (n=11 648). B, In patients without PES at index PCI (n=8864). Log-rank P values for treatment effect in each DAPT score category are presented according to time interval, and interaction P values on the additive scale are presented for each time period. See online-only Data Supplement Table II. DAPT indicates Dual Antiplatelet Therapy; MI, myocardial infarction; PCI, percutaneous coronary intervention; and PES, paclitaxel-eluting stents.

  Show Less

Pages